{'52WeekChange': 0.6753293,
 'SandP52WeekChange': 0.0644362,
 'address1': '50 Northern Avenue',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 278.51,
 'askSize': 1000,
 'averageDailyVolume10Day': 1233362,
 'averageVolume': 1822080,
 'averageVolume10days': 1233362,
 'beta': 0.937815,
 'beta3Year': None,
 'bid': 276.5,
 'bidSize': 800,
 'bookValue': 24.941,
 'category': None,
 'circulatingSupply': None,
 'city': 'Boston',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 282.63,
 'dayLow': 276.5001,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': 1.244,
 'enterpriseToEbitda': 39.089,
 'enterpriseToRevenue': 14.223,
 'enterpriseValue': 68548526080,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 285.72687,
 'fiftyTwoWeekHigh': 306.08,
 'fiftyTwoWeekLow': 165.23,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 258882608,
 'forwardEps': 10.93,
 'forwardPE': 25.479412,
 'fromCurrency': None,
 'fullTimeEmployees': 3000,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.0013600001,
 'heldPercentInstitutions': 0.97827005,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 967075200,
 'lastSplitFactor': '2:1',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/vrtx.com',
 'longBusinessSummary': 'Vertex Pharmaceuticals Incorporated engages in '
                        'developing and commercializing therapies for treating '
                        'cystic fibrosis. The company markets SYMDEKO/SYMKEVI, '
                        'ORKAMBI, and KALYDECO to treat patients with cystic '
                        'fibrosis who have specific mutations in their cystic '
                        'fibrosis transmembrane conductance regulator gene; '
                        'and TRIKAFTA for the treatment of patients with CF 12 '
                        'years of age or older who have at least one F508del '
                        'mutation in the cystic fibrosis transmembrane '
                        'conductance regulator, or CFTR, gene. Its pipeline '
                        'includes Pipeline for Alpha-1 antitrypsin deficiency '
                        'that is in Phase 2 clinical trial; VX-864, a second '
                        'investigational small molecule corrector for the '
                        'treatment of AAT deficiency, which is in Phase 1 '
                        'clinical trial; and VX-147 that completed a Phase 1 '
                        'clinical trial for the treatment of APOL1-mediated '
                        'focal segmental glomerulosclerosis, or FSGS, and '
                        'other serious kidney diseases. The company sells its '
                        'products primarily to specialty pharmacy and '
                        'specialty distributors in the United States, as well '
                        'as specialty distributors and retail chains, and '
                        'hospitals and clinics internationally. Vertex '
                        'Pharmaceuticals Incorporated has collaborations with '
                        'CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; '
                        'Moderna Therapeutics, Inc.; Genomics plc; Merck KGaA; '
                        'Darmstadt, Germany; X-Chem, Inc.; Janssen '
                        'Pharmaceuticals, Inc.; Merck KGaA; Kymera '
                        'Therapeutics; Ribometrix, Inc.; Molecular Templates, '
                        'Inc.; and Affinia Therapeutics. The company was '
                        'founded in 1989 and is headquartered in Boston, '
                        'Massachusetts.',
 'longName': 'Vertex Pharmaceuticals Incorporated',
 'market': 'us_market',
 'marketCap': 72206049280,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_36235',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': 1510931968,
 'nextFiscalYearEnd': 1640908800,
 'open': 281.78,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 1.13,
 'phone': '617 341 6100',
 'previousClose': 284.46,
 'priceHint': 2,
 'priceToBook': 11.165952,
 'priceToSalesTrailing12Months': 14.982084,
 'profitMargins': 0.31350002,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 282.63,
 'regularMarketDayLow': 276.5001,
 'regularMarketOpen': 281.78,
 'regularMarketPreviousClose': 284.46,
 'regularMarketPrice': 281.78,
 'regularMarketVolume': 1775729,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 259276992,
 'sharesPercentSharesOut': 0.0167,
 'sharesShort': 4332159,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 3908632,
 'shortName': 'Vertex Pharmaceuticals Incorpor',
 'shortPercentOfFloat': 0.0167,
 'shortRatio': 2.33,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'VRTX',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': 5.778,
 'trailingPE': 48.198338,
 'twoHundredDayAverage': 256.13138,
 'volume': 1775729,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.vrtx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02210'}